SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Porrata, L. F. Articles by Markovic, S. N. Search for Related Content PubMed PubMed Citation Articles by Porrata, L. F. Articles by Markovic, S. N. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 August 2001, Vol. 98, No. 3, pp. 579-585 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma Luis F. Porrata, Morie A. Gertz, David J. Inwards, Mark R. Litzow, Martha Q. Lacy, Ayalew Tefferi, Dennis A. Gastineau, Angela Dispenzieri, Stephen M. Ansell, Ivana N. M. Micallef, Susan M. Geyer, and Svetomir N. Markovic From the Division of Hematology, Department of Internal Medicine; and the Cancer Center Statistics, Section of Biostatistics, Mayo Clinic, 200 First St SW, Rochester, MN 55905. Autologous stem cell transplantation (ASCT) improves survival in patients with previously untreated multiple myeloma (MM) and relapsed, chemotherapy-sensitive, aggressive non-Hodgkin lymphoma (NHL). Lower relapse rates seen in allogeneic stem cell transplantation have been related to early absolute lymphocyte count (ALC) recovery as a manifestation of early graft-verus-tumor effect. In ASCT, the relation between ALC recovery and clinical outcomes in MM and NHL was not previously described. This is a retrospective study of patients with MM and NHL who underwent ASCT at the Mayo Clinic between 1987 and 1999. The ALC threshold was determined at 500 cells/µL on day 15 after ASCT. The study identified 126 patients with MM and 104 patients with NHL. The median overall survival (OS) and progression-free survival (PFS) times for patients with MM were significantly longer in patients with an ALC of 500 cells/µL or more than patients with an ALC of fewer than 500 cells/µL (33 vs 12 months, P < .0001; 16 vs 8 months, P < .0003, respectively). For patients with NHL, the median OS and PFS times were significantly longer in patients with an ALC of 500 cells/µL or more versus those with fewer than 500 cells/µL (not reached vs 6 months, P < .0001; not reached vs 4 months, P < .0001, respectively). Multivariate analysis demonstrated day 15 ALC to be an independent prognostic indicator for OS and PFS rates for both groups of patients. In conclusion, ALC is correlated with clinical outcome and requires further study. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. P. Rapoport, E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H.-B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al. Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells Clin. Cancer Res., July 1, 2009; 15(13): 4499 - 4507. [Abstract] [Full Text] [PDF] L. F. Porrata, M. A. Gertz, M. R. Litzow, M. Q. Lacy, A. Dispenzieri, D. J. Inwards, S. M. Ansell, I. N.M. Micallef, D. A. Gastineau, M. Elliott, et al. Early Lymphocyte Recovery Predicts Superior Survival after Autologous Hematopoietic Stem Cell Transplantation for Patients with Primary Systemic Amyloidosis Clin. Cancer Res., February 1, 2005; 11(3): 1210 - 1218. [Abstract] [Full Text] [PDF] Y. Nieto, E. J. Shpall, I. K. McNiece, S. Nawaz, J. Beaudet, S. Rosinski, J. Pellom, V. Slat-Vasquez, P. A. McSweeney, S. I. Bearman, et al. Prognostic Analysis of Early Lymphocyte Recovery in Patients with Advanced Breast Cancer Receiving High-Dose Chemotherapy with an Autologous Hematopoietic Progenitor Cell Transplant Clin. Cancer Res., August 1, 2004; 10(15): 5076 - 5086. [Abstract] [Full Text] [PDF] G. G. Laport, B. L. Levine, E. A. Stadtmauer, S. J. Schuster, S. M. Luger, S. Grupp, N. Bunin, F. J. Strobl, J. Cotte, Z. Zheng, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation Blood, September 15, 2003; 102(6): 2004 - 2013. [Abstract] [Full Text] [PDF] G. Ferrandina, L. Pierelli, A. Perillo, S. Rutella, M. Ludovisi, G. Leone, S. Mancuso, and G. Scambia Lymphocyte Recovery in Advanced Ovarian Cancer Patients after High-Dose Chemotherapy and Peripheral Blood Stem Cell Plus Growth Factor Support: Clinical Implications Clin. Cancer Res., January 1, 2003; 9(1): 195 - 200. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020